about
Buttonhole cannulation and clinical outcomes in a home hemodialysis cohort and systematic reviewPrimary and tertiary health professionals' views on the health-care of patients with co-morbid diabetes and chronic kidney disease - a qualitative studyCardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study.25-Hydroxyvitamin D levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) studyThe association between body mass index and mortality in incident dialysis patients.Predictors and outcomes of transfers from peritoneal dialysis to hemodialysisThe Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modificationsThe Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative StudyAn Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia and New Zealand Dialysis and Transplantation Registry).Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis.Early serum creatinine accurately predicts acute kidney injury post cardiac surgery.Risk factors for peritoneal dialysis-related peritonitis: can we reduce the incidence and improve patient selection?Total volume and composition of fluid intake and mortality in older women: a cohort study.Blood pressure and blood volume: acute and chronic considerations in hemodialysis.Optimal hemodialysis vascular access in the elderly patient.Elderly patients with CKD--dilemmas in dialysis therapy and vascular access.Debate: Should dialysis at home be mandatory for all suitable ESRD patients?: home-based dialysis therapies are the second choice after transplantation.Vitamin D therapy in chronic kidney disease: back to the future?The association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney disease.Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease.Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study.Association between initial and pretransplant dialysis modality and graft and patient outcomes in live- and deceased-donor renal transplant recipients.Physical inactivity and chronic kidney disease in Australian adults: the AusDiab study.Cystatin C estimated glomerular filtration rate and all-cause and cardiovascular disease mortality risk in the general population: AusDiab study.The fragility of significant results underscores the need of larger randomized controlled trials in nephrology.Fatal Dialysis Vascular Access Hemorrhage.Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.Dialysis modality, vascular access and mortality in end-stage kidney disease: A bi-national registry-based cohort study.Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations.Clustering and Residual Confounding in the Application of Marginal Structural Models: Dialysis Modality, Vascular Access, and Mortality.How Can the Complications of Central Vein Catheters Be Reduced?: Intraluminal Prophylaxis and Management of Catheter Infections: Role of Antibiotic Locks.Different faces of Nocardia infection in renal transplant recipients.Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study.Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion.Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population.Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a case-control study.Can We Predict the Unpredictable after Vascular Access Creation?
P50
Q26861548-ABFAF150-3AA3-459F-8DE7-5809FBA1F3AAQ27311887-AB8D40F8-0C94-49E2-A3D5-8963A254CBE2Q28167686-3B0C3045-B3B1-4B8C-A2A3-C3958D2C4C05Q33905988-E2D0FA09-7859-4A79-92DE-B1C0BFF793DAQ34324553-80F2E2AF-34CB-4DEC-B879-6B86F3732FF1Q34712804-69BC68B6-AA93-43F6-B7F6-9BFA24CB4258Q35647441-CC429414-BC79-4D74-B8DF-8819C147AE64Q35676161-CA482BCE-FCE5-44BD-B5E3-9FC47BDB03B2Q35885097-E8843231-8964-44D8-99A4-AB197509B884Q35922687-E6574CEE-BD93-4E27-9260-63847AAF628BQ35977529-D1B699E9-F167-4AC4-951A-7BF295E3BAA2Q36311168-9258183E-A957-459E-B89C-9AAC1BF35767Q36820018-669E9DEB-F766-4843-9683-7131AFDF68ADQ37728244-4BFFF564-80AD-4977-8132-F8361060C4FFQ38045940-F2826995-F1E5-4F77-A8DC-0F635D4BECEAQ38061698-D1380F7E-759E-4D91-A2AE-C993C891A5DEQ38168049-4BBD29F6-D62D-455C-8CD3-1ABE3804BFFEQ38284256-ED9CC976-E2B4-4DE9-BEDA-DC0CE3BFA71AQ38543627-937B0F1D-6FFE-406C-A1D7-DFBE1C058DAAQ38694577-1A7EB081-C30C-47BE-9E02-847C22864DEBQ39028412-A43B2FF3-6108-4E5D-9DFC-80F2EB29C346Q39288345-DCD3EC67-BA16-496A-8310-266ECEB60925Q39584646-964E5EFE-40C3-4AA3-ABDC-B3684E1D952DQ39925939-38B37599-0B7A-483B-80D7-71EC4D5DCCABQ39951163-50F32A84-71E3-4975-8F9C-7A2902E25C00Q40103533-31CD11AB-3AEC-43FD-9FBD-9A6AA6240355Q40136405-2D94817A-2D35-49F3-9178-B2BF0DEC334DQ40149564-6147D8DE-0CA3-499A-B5E7-DC4761DEBA9BQ40249494-68CB71FA-2300-40E4-BC88-9BB67305F346Q40329416-B735AE13-0F94-4D95-8A78-CC89EFDBB6F9Q40597598-7E137EE4-69D3-4B96-98C9-E893BEA862DDQ40792055-C719E553-BC04-4D5F-8544-1E53BDD99DA9Q40814304-C2ACBAF8-E860-48D0-AAAC-0A2A4DF18F49Q40868213-8E092C95-8B03-464B-AF3E-5615C690CB9DQ40926527-F12B5F3C-70B5-4190-802A-BF8C3101D3F8Q40956867-5CCE8B59-7082-4472-88FF-9813AD8413C6Q41335103-02C23A05-B7A6-4ADE-BBD8-FA7481FDF9E8Q41553370-D5F701A7-3798-4025-B7B3-A7997B4EE353Q42242898-E3B18343-3C79-48AC-BE49-EF7BBE528B1FQ42386494-A79F8F66-5DA8-4F38-8BA6-85B5EA669B13
P50
description
researcher
@en
wetenschapper
@nl
name
Kevan R Polkinghorne
@en
Kevan R Polkinghorne
@nl
type
label
Kevan R Polkinghorne
@en
Kevan R Polkinghorne
@nl
prefLabel
Kevan R Polkinghorne
@en
Kevan R Polkinghorne
@nl
P106
P31
P496
0000-0002-9851-002X